Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
FDA Approval (4)
284 Articles Available
4
12
Can't find what you're looking for? Try our
advanced search
.
FDA Approval
FDA Approves REVLIMID® (Lenalidomide) in Combination With Rituximab for the Treatment of Follicular Lymphoma or Marginal Zone Lymphoma
PR-M05-19-NI-085
FDA Approval
FDA Approves First Anticoagulant Blood Thinner for Use in Children
PAO-M05-19-NI-028
FDA
FDA Permits Marketing of First Diagnostic Test to Aid in Detecting Prosthetic Joint Infections
PR-M05-19-NI-079
FDA Approval
Second Generation On-the-Go ECG Device Gets FDA Approval
PAO-M05-19-NI-023
FDA Approval
FDA Approves Venetoclax for CLL and SLL
PR-M05-19-NI-057
FDA Approval
Genentech Announces FDA Approval for Venclexta Plus Gazyva for People With Previously Untreated Chronic Lymphocytic Leukemia
PR-M05-19-NI-050
Drug Approval
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
PR-M05-19-NI-036
FDA
The FDA Changes the Drug Approval Process
PAO-M05-19-NI-014
Generic
First Generic Nalaxone Nasal Spray Approved by FDA
PAO-M05-19-NI-006
ADHD
First Medical Device Cleared by FDA to Treat Childhood ADHD
PAO-M05-19-NI-002
FDA Approval
FDA Approved Keytruda for Kidney Cancer Sooner than Expected
PAO-M05-19-NI-001
FDA Approval
FDA Approves Trade Name Lexette (TM) (Halobetasol Propionate) Foam, 0.05%
PR-M05-19-NI-006
FDA Approval
FDA Approves Bausch Health's DUOBRII™ (Halobetasol Propionate And Tazarotene) Lotion 0.01%/0.045% For Plaque Psoriasis In Adults
PR-M04-19-NI-082
FDA Approval
J&J’s Bladder Cancer Drug Gets Accelerated FDA Approval
PAO-M04-19-NI-019
FDA Approval
FDA Approves First Targeted Therapy for Metastatic Bladder Cancer
PR-M04-19-NI-050
FDA Approval
FDA Approves New Treatment for Osteoporosis in Postmenopausal Women at High Risk of Fracture
PR-M04-19-NI-041
Allogeneic CAR-T
FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients
PR-M04-19-NI-028
FDA Approval
Luye Pharma's Rykindo® Expected to Be the First Chinese Innovative Drug to Receive U.S. FDA Approval
PR-M04-19-NI-016
FDA Approval
CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
PR-M04-19-NI-013
FDA Approval
First Patient Treated for Severe Emphysema with the FDA-Approved Spiration® Valve System
PR-M04-19-NI-010
FDA Approval
UCB Given FDA Okay for Anti-Arthritis Drug
PAO-M04-19-NI-008
FDA
Janssen Aims for Supplemental U.S. FDA Approval for INVOKANA®
PAO-M04-19-NI-007
FDA Approval
FDA Approves Treatment for Patients with a Type of Inflammatory Arthritis
PR-M04-19-NI-001
FDA Approval
FDA Approves New Device for Treating Moderate to Severe Chronic Heart Failure in Patients
PR-M03-19-NI-068
«
4
12
»
.svg)
